[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100510810":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":33,"locations":42,"responsibleParty":151,"collaborators":24,"id":153,"slug":24,"hasResults":154,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":154,"sex":160,"minAge":161,"maxAge":24,"enrollmentInfo":162,"targetDuration":24,"studyType":165,"phases":166,"briefSummary":168,"conditions":169,"keywords":172,"overallStatus":45,"whyStopped":24,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":188},{"fullName":5,"class":6},"VA Office of Research and Development","FED",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Metoprolol Succinate","ACTIVE_COMPARATOR","Depending on baseline type and dose of beta blocker:\n\n* 25 mg once daily (12.5 mg once daily if \\> NYHA class II)\n* 50 mg (or 25 mg) once daily\n* 100 mg (or 50 mg) once daily\n* 200 mg (or 100 mg titrated to 200 mg) once daily",[13],"Drug: Metoprolol Succinate",{"label":15,"type":10,"description":16,"interventionNames":17},"Carvedilol","Depending on baseline type and dose of beta blocker:\n\n* 3.125 mg twice daily\n* 6.25 mg twice daily\n* 12.5 mg twice daily\n* 25 mg twice daily (may titrate to 5 0mg twice daily if \\> 85 kg)",[18],"Drug: Carvedilol",[20,25],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","a dialyzable, beta-1 selective beta blocker",[9],null,{"type":21,"name":15,"description":26,"armGroupLabels":27,"otherNames":24},"a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties",[15],[29],{"name":30,"affiliation":31,"role":32},"Areef Ishani, MD MS","Minneapolis VA Health Care System, Minneapolis, MN","STUDY_CHAIR",[34,38],{"name":35,"role":36,"phone":24,"phoneExt":24,"email":37},"Christopher M Donnelly","CONTACT","Christopher.Donnelly2@va.gov",{"name":39,"role":36,"phone":40,"phoneExt":24,"email":41},"Jade Fiotto","(617) 232-9500","Jade.Fiotto@va.gov",[43,60,72,84,96,112,127,139],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":56},"VA Long Beach Healthcare System, Long Beach, CA","RECRUITING","Long Beach","California","90822","United States",{"type":51,"coordinates":52},"Point",[53,54],-118.18923,33.76696,{"lat":54,"lon":53},[57],{"name":58,"role":36,"phone":24,"phoneExt":24,"email":59},"Srihari Raju, MD","Srihari.Raju@va.gov",{"facility":61,"status":45,"city":62,"state":63,"zip":64,"country":49,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"North Florida\u002FSouth Georgia Veterans Health System, Gainesville, FL","Gainesville","Florida","32608-1135",{"type":51,"coordinates":66},[67,68],-82.32483,29.65163,{"lat":68,"lon":67},[71],{"name":58,"role":36,"phone":24,"phoneExt":24,"email":59},{"facility":73,"status":45,"city":74,"state":75,"zip":76,"country":49,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"Atlanta VA Medical and Rehab Center, Decatur, GA","Decatur","Georgia","30033-4004",{"type":51,"coordinates":78},[79,80],-84.29631,33.77483,{"lat":80,"lon":79},[83],{"name":58,"role":36,"phone":24,"phoneExt":24,"email":59},{"facility":85,"status":45,"city":86,"state":87,"zip":88,"country":49,"cosmosGeoPoint":89,"geoPoint":93,"contacts":94},"Iowa City VA Health Care System, Iowa City, IA","Iowa City","Iowa","52246-2292",{"type":51,"coordinates":90},[91,92],-91.53017,41.66113,{"lat":92,"lon":91},[95],{"name":58,"role":36,"phone":24,"phoneExt":24,"email":59},{"facility":97,"status":98,"city":99,"state":100,"zip":101,"country":49,"cosmosGeoPoint":102,"geoPoint":106,"contacts":107},"VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA","NOT_YET_RECRUITING","Boston","Massachusetts","02130-4817",{"type":51,"coordinates":103},[104,105],-71.05977,42.35843,{"lat":105,"lon":104},[108],{"name":109,"role":36,"phone":110,"phoneExt":24,"email":111},"Jade Fiotto, MPH","617-232-9500","jade.fiotto@va.gov",{"facility":31,"status":45,"city":113,"state":114,"zip":115,"country":49,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"Minneapolis","Minnesota","55417-2309",{"type":51,"coordinates":117},[118,119],-93.26384,44.97997,{"lat":119,"lon":118},[122,126],{"name":30,"role":36,"phone":123,"phoneExt":124,"email":125},"612-467-4431","314431","areef.ishani@va.gov",{"name":30,"role":32,"phone":24,"phoneExt":24,"email":24},{"facility":128,"status":45,"city":129,"state":130,"zip":131,"country":49,"cosmosGeoPoint":132,"geoPoint":136,"contacts":137},"Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE","Omaha","Nebraska","68105-1850",{"type":51,"coordinates":133},[134,135],-95.94043,41.25626,{"lat":135,"lon":134},[138],{"name":58,"role":36,"phone":24,"phoneExt":24,"email":59},{"facility":140,"status":45,"city":141,"state":142,"zip":143,"country":49,"cosmosGeoPoint":144,"geoPoint":148,"contacts":149},"New Mexico VA Health Care System, Albuquerque, NM","Albuquerque","New Mexico","87108-5153",{"type":51,"coordinates":145},[146,147],-106.65114,35.08449,{"lat":147,"lon":146},[150],{"name":58,"role":36,"phone":24,"phoneExt":24,"email":59},{"type":152,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100510810",false,"NCT05931276","CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes","CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes (BRAVO)","BRAVO","Inclusion Criteria:\n\n* On hemodialysis\n* Received one of the following beta blockers through the VA pharmacy: metoprolol (succinate or tartrate), atenolol, labetalol, carvedilol, bisoprolol\n\nExclusion Criteria:\n\n* Impaired decision-making capacity\n* Patients not receiving carvedilol who have a history of asthma\n* known hypersensitivity to any component of either drug\n* Provider unwilling to sign a new medication order for a randomized patient\n* No surrogate consent will be allowed","ALL","18 Years",{"count":163,"type":164},2540,"ESTIMATED","INTERVENTIONAL",[167],"PHASE3","The investigators aim to determine, using a point-of-care randomized controlled trial design, if hemodialysis patients, who are randomized to metoprolol succinate (a dialyzable, beta-1 selective beta blocker), have an improved cardiovascular outcome compared to those randomized to carvedilol (a non-dialyzable, non-selective beta blocker with alpha-1 antagonist properties). The investigators will also examine intervention practices to identify components that best support engagement and sustainability.",[170,171],"End-Stage Kidney Disease","End-Stage Renal Disease",[173,174,175,176,177,9,15,178],"Dialysis","beta-Blockers, Adrenergic","Cardiovascular Diseases","Point of Care Research","Comparative Effectiveness Research","Hemodialysis","2026-01-07",{"date":181,"type":182},"2026-01-09","ACTUAL",{"date":184,"type":182},"2024-05-22",{"date":186,"type":164},"2028-12-31",{"name":5,"class":6},8]